NEW YORK (GenomeWeb) – Premas Life Sciences announced today that it has signed an agreement to acquire the exclusive distribution rights in India to IncellDx's portfolio of immune-oncology and oncology diagnostic products.

Included in the deal are IncellDx's OncoTect single-cell assay for quantifying PD-L1 on tumor cells and immune cell subtypes; its single-cell assay for HPV E6/E7 mRNA detection in cervical samples; and its IncellPrep single-cell preparation kit for solid tissues including tumors.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.